# Viridian Therapeutics, Inc. Common Stock (VRDN)

Viridian Therapeutics (VRDN) stock shows strong analyst support and a recent public offering, but faces declining social media engagement.

### About Viridian Therapeutics, Inc. Common Stock
Viridian Therapeutics, Inc. is a biotechnology company focused on therapies for thyroid eye disease.  
Viridian Therapeutics, Inc. Common Stock uses the ticker $VRDN for trading. Listed in the [Stocks](/list/stocks) category within the [Healthcare](/list/stocks/healthcare) sectors.

### Insights
- Viridian Therapeutics, Inc. Common Stock (VRDN) social dominance is up 70.83% from the previous [--] months.
- Viridian Therapeutics, Inc. Common Stock (VRDN) engagements is up 357.06% from the previous week.
- Viridian Therapeutics, Inc. Common Stock (VRDN) mentions is up 75.44% from the previous month.

### Price: $27.90
![Price Line Chart](https://lunarcrush.com/gi/w:600/t:$vrdn/c:line/m:close/iv:1d.svg)  
[Price 24-Hour Time-Series Raw Data](/topic/$vrdn/time-series/close.tsv)  
The stock price has reached a 52-week high, supported by positive analyst sentiment and a successful public offering, despite a recent 24-hour dip and declining social media engagement.  

24-Hour: -3.65%
7-Day: -5.17%
30-Day: -16.12%

1-Year High: $33.80 on 2026-01-14  
1-Year Low: $11 on 2025-04-08  
  
  
### AltRank: [---]
![AltRank Line Chart](https://lunarcrush.com/gi/w:600/t:$vrdn/c:line/m:alt_rank/iv:1d.svg)  
[AltRank 24-Hour Time-Series Raw Data](/topic/$vrdn/time-series/alt_rank.tsv)  
Viridian Therapeutics, Inc. Common Stock (VRDN) is currently AltRank #368 based on combined combined social and market metrics
Daily Average: [-----]  
[--] Week: [---] [----]  
[--] Month: [---] [----]  
[--] Months: [---] +357  
[--] Year: [---] +139  
1-Year High: [-----] on 2026-01-26  
1-Year Low: [--] on 2025-11-23  
  
  
### Galaxy Score: [-----]
![Galaxy Score Line Chart](https://lunarcrush.com/gi/w:600/t:$vrdn/c:line/m:galaxy_score/iv:1d.svg)  
[Galaxy Score 24-Hour Time-Series Raw Data](/topic/$vrdn/time-series/galaxy_score.tsv)  
Current Value: [-----]  
Daily Average: [--]  
[--] Week: [--] +4  
[--] Month: [--] +36  
1-Year High: [--] on 2025-12-22  
1-Year Low: [--] on 2025-12-02  
  
  
### Engagements: [------] (24h)
![Engagements Line Chart](https://lunarcrush.com/gi/w:600/t:$vrdn/c:line/m:interactions/iv:1d.svg)  
[Engagements 24-Hour Time-Series Raw Data](/topic/$vrdn/time-series/interactions.tsv)  
Current Value: [------]  
Daily Average: [-----]  
[--] Week: [------] +357%  
[--] Month: [-------] +42%  
[--] Months: [-------] +59%  
[--] Year: [---------] -48%  
1-Year High: [------] on 2025-12-14  
1-Year Low: [--] on 2025-04-21  

Engagements by network (24h):
Reddit: [--]
News: [--]
YouTube: [--]
X: [------]
TikTok: [--]

  
  
### Mentions: [--] (24h)
![Mentions Line Chart](https://lunarcrush.com/gi/w:600/t:$vrdn/c:line/m:posts_active/iv:1d.svg)  
[Mentions 24-Hour Time-Series Raw Data](/topic/$vrdn/time-series/posts_active.tsv)  
Current Value: [--]  
Daily Average: [--]  
[--] Week: [---] +10%  
[--] Month: [---] +75%  
[--] Months: [-----] -14%  
[--] Year: [-----] +74%  
1-Year High: [---] on 2025-06-28  
1-Year Low: [--] on 2025-10-11  

Mentions by network (24h):
Reddit: [--]
News: [--]
YouTube: [--]
X: [--]
TikTok: [--]

  
  
### Creators: [--] (24h)
![Creators Line Chart](https://lunarcrush.com/gi/w:600/t:$vrdn/c:line/m:contributors_active/iv:1d.svg)  
[Creators 24-Hour Time-Series Raw Data](/topic/$vrdn/time-series/contributors_active.tsv)  
[--] unique social accounts have posts mentioning Viridian Therapeutics, Inc. Common Stock (VRDN) in the last [--] hours which is down 6.10% from [--] in the previous [--] hours
Daily Average: [--]  
[--] Week: [--] +1.60%  
[--] Month: [---] +66%  
[--] Months: [---] -48%  
[--] Year: [-----] +160%  
1-Year High: [---] on 2025-06-28  
1-Year Low: [--] on 2025-10-11  

The most influential creators that mention Viridian Therapeutics, Inc. Common Stock in the last [--] hours

| Creator                                              | Rank | Followers | Posts | Engagements |
| -------                                              | ---- | --------- | ----- | ----------- |
| [@BiopharmIQ](/creator/twitter/BiopharmIQ)           | [--]    | [------]    | [--]     | [-----]       |
| [@Andre_AGTC](/creator/twitter/Andre_AGTC)           | [--]    | [-----]     | [--]     | [-----]       |
| [@stockmktgenius](/creator/twitter/stockmktgenius)   | [--]    | [------]    | [--]     | [--]          |
| [@StockConsultant](/creator/twitter/StockConsultant) | [--]    | [-----]     | [--]     | [--]           |
| [@MarcJacksonLA](/creator/twitter/MarcJacksonLA)     | [--]    | [-----]     | [--]     | [--]           |

[View More](/list/creators/$vrdn/100)
  
  
### Sentiment: 85%
![Sentiment Line Chart](https://lunarcrush.com/gi/w:600/t:$vrdn/c:line/m:sentiment/iv:1d.svg)  
[Sentiment 24-Hour Time-Series Raw Data](/topic/$vrdn/time-series/sentiment.tsv)  
Current Value: 85%  
Daily Average: 87%  
[--] Week: 100% no change  
[--] Month: 87% +9%  
[--] Months: 87% -13%  
[--] Year: 87% +4%  
1-Year High: 100% on 2025-02-16  
1-Year Low: 14% on 2025-09-22  

Most Supportive Themes:
- Analyst Upgrades and Price Targets: (40%) Financial analysts have increased their price targets for Viridian Therapeutics, indicating positive sentiment from the financial community.
- Public Offering and Financial Health: (30%) The company's recent public offering has strengthened its financial position, providing resources for future development.
- Regulatory Milestones: (20%) The submission of a Biologics License Application (BLA) to the FDA for veligrotug is a significant step towards potential market approval.
  
Most Critical Themes:
- Declining Social Media Engagement: (15%) Despite positive company news, social media interest is decreasing, with notable drops in engagement and mentions.
  
  
  
### Social Dominance: 0.0039%
![Social Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$vrdn/c:line/m:social_dominance/iv:1d.svg)  
[Social Dominance 24-Hour Time-Series Raw Data](/topic/$vrdn/time-series/social_dominance.tsv)  
Current Value: 0.0039%  
Daily Average: 0.00512%  
[--] Week: 0.00356% +0.00106%  
[--] Month: 0.0041% +0.0009000000000000002%  
[--] Months: 0.0041% -0.0042%  
[--] Year: 0.0041% -0.0039%  
1-Year High: 0.033% on 2025-06-29  
1-Year Low: 0.0005% on 2025-10-11  
  
  
### Market Dominance: 0.00302%
![Market Dominance Line Chart](https://lunarcrush.com/gi/w:600/t:$vrdn/c:line/m:market_dominance/iv:1d.svg)  
[Market Dominance 24-Hour Time-Series Raw Data](/topic/$vrdn/time-series/market_dominance.tsv)  
Current Value: 0.00302%  
Daily Average: 0%  
1-Year High: 0.129% on 2026-02-06  
1-Year Low: 0.00302% on 2026-02-14  
  
  
### Market Cap: $2,662,832,023
![Market Cap Line Chart](https://lunarcrush.com/gi/w:600/t:$vrdn/c:line/m:market_cap/iv:1d.svg)  
[Market Cap 24-Hour Time-Series Raw Data](/topic/$vrdn/time-series/market_cap.tsv)  
Current Value: $2,662,832,023  
Daily Average: $3,003,757,510  
[--] Week: $2,643,743,622 -4.20%  
[--] Month: $2,662,832,023 -16%  
1-Year High: $3,224,031,030 on 2026-01-14  
1-Year Low: $2,662,832,023 on 2026-02-13  

### Top Viridian Therapeutics, Inc. Common Stock Social Posts
Top posts by engagements in the last [--] hours

*Showing a maximum of [--] top social posts without a LunarCrush subscription.*

"A new development in the advancement of potential treatments for thyroid eye disease (TED): The FDA has accepted a BLA from our corporate partner Viridian Therapeutics (@viridianthera) for veligrotug an investigational therapy for people living with TED. The application has received Priority Review. https://www.viridiantherapeutics.com/patients/community-corner/ https://www.viridiantherapeutics.com/patients/community-corner/"  
[X Link](https://x.com/FightBlindness/status/2022766570359988726) [@FightBlindness](/creator/x/FightBlindness) 2026-02-14T20:15Z 14.8K followers, [---] engagements


"#Deeptrack Feb 13'26 Massive $XBI put 22% of portfolio Vary bearish move👀 Changed position of interest $XBI put New #1 $IMVT +19% #2 $AXSM +28% #7 $CYTK -22% #6 $VRDN -53% #19"  
[X Link](https://x.com/Andre_AGTC/status/2022739154920985013) [@Andre_AGTC](/creator/x/Andre_AGTC) 2026-02-14T18:26Z [----] followers, [----] engagements


"Each quarter we identify major catalyst events 🚨 Likely to move the stock +/- by 20% $NKTR Rezpegaldesleukin (NKTR-358) Ph2b $RGNX RGX-202 Ph2/3 $VRDN Veligrotug (formerly VRDN-001) PDUFA Access our FREE Big Mover Report below 👇 https://www.offers.bpiq.com/big-mover-lpmo=jun https://www.offers.bpiq.com/big-mover-lpmo=jun"  
[X Link](https://x.com/BiopharmIQ/status/2022703292162445333) [@BiopharmIQ](/creator/x/BiopharmIQ) 2026-02-14T16:03Z 28.9K followers, [---] engagements


"My watch list of catalysts- update 👍$NKTR 36w AD 👍$BBIO Ph3 ACH $AXSM PDUFA ADA $XENE Ph3 FOS $PRAX NDA ET DEE $RVMD Ph3 PDAC L2 $ALMS Ph2b SLE $TVTX PDUFA FSGS $VRDN Ph3 TED $MLTX Ph2 ax SpA $MLYS Ph2 OSA $CMPS Ph3 TRD $HELP Ph2 GAD $PVLA Ph3 mLM My watch list of catalysts 👍$NKTR 36w AD 👍$BBIO Ph3 ACH $AXSM PDUFA ADA $XENE Ph3 FOS $PRAX NDA ET DEE $RVMD Ph3 PDAC L2 $ALMS Ph2b SLE $TVTX PDUFA FSGS $VRDN Ph3 TED $MLTX Ph2 ax SpA $MLYS Ph2 OSA $CMPS Ph3 TRD $HELP Ph2 GAD My watch list of catalysts 👍$NKTR 36w AD 👍$BBIO Ph3 ACH $AXSM PDUFA ADA $XENE Ph3 FOS $PRAX NDA ET DEE $RVMD Ph3 PDAC"  
[X Link](https://x.com/Andre_AGTC/status/2022077136581083568) [@Andre_AGTC](/creator/x/Andre_AGTC) 2026-02-12T22:35Z [----] followers, [----] engagements

Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing